Keyphrases
Differentiated Thyroid Cancer
73%
Thyroid Dysfunction
64%
Childhood Cancer Survivors
64%
Differentiated Thyroid Carcinoma
55%
Dutch
54%
Thyroid Cancer
51%
Childhood Cancer
48%
Antineoplastic Drugs
48%
Risk Factors
46%
Medullary Thyroid Cancer
43%
Incidence Trends
43%
Netherlands
24%
Pediatric Thyroid Carcinoma
22%
Tomography
21%
Emissive
21%
Thyroglobulin Level
21%
National Recommendations
21%
AAPC
21%
PTEN Hamartoma Tumor Syndrome
21%
Clinical Considerations
21%
Positron
21%
Hyperthyroidism
21%
Fluorodeoxyglucose
21%
Childhood Brain Tumor Survivors
21%
Hypothalamic-pituitary Dysfunction
21%
Thyroid Patients
21%
Toddlers
21%
Prevalence Factors
21%
Radiotherapy
15%
Prevalence Risk
14%
Cancer Treatment
13%
Average Annual Percentage Change
12%
European Recommendations
10%
Cochrane Review
10%
Thyroid Function Parameters
10%
Inconvenience
10%
Apologizing
10%
Hypothyroidism
10%
Thyroid Nodule
10%
Free Thyroxine
10%
Brain Tumor Survivors
9%
Incidence Rate
9%
Overall Survival
9%
Pediatric
9%
Primary Hypothyroidism
8%
Brain Tumor
8%
Young Age
7%
Expert Opinion
7%
Small Tumor
6%
Rising Incidence
6%
Medicine and Dentistry
Differentiated Thyroid Cancer
100%
Childhood Cancer
86%
Thyroid Cancer
50%
Prevalence
49%
Thyroid Disease
44%
Pediatrics
30%
Anticarcinogen
27%
Intracranial Tumor
27%
Radiation Therapy
23%
Thyroglobulin
21%
Fluorodeoxyglucose
21%
Tomography
21%
Systematic Review
21%
Cancer Syndrome
21%
Hamartoma
21%
Thyroid Gland
15%
Hypothyroidism
13%
Chemotherapy
11%
Immunotherapy
10%
Thyroid Nodule
10%
Hyperthyroidism
10%
Cancer Therapy
7%
Neoplasm
7%
Iodine 131
7%
Risk Factor Surveillance
5%
Papillary Thyroid Cancer
5%
Sequela
5%
Thyroid Function
5%
(3 Iodobenzyl)guanidine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Differentiated Thyroid Cancer
95%
Childhood Cancer
86%
Thyroid Cancer
50%
Thyroid Disease
44%
Anticarcinogen
43%
Hamartoma
21%
Tumor Syndrome
21%
Thyroglobulin
21%
Fluorodeoxyglucose
21%
Malignant Neoplasm
20%
Hypothyroidism
13%
Chemotherapy
11%
Thyroxine
10%
Hyperthyroidism
10%
Prevalence
8%
Overall Survival
6%
Neoplasm
5%